Drug Profile
Lorecivivint - Biosplice Therapeutics
Alternative Names: Adavivint - Biosplice Therapeutics; SM-04690Latest Information Update: 22 Apr 2024
Price :
$50
*
At a glance
- Originator Samumed
- Developer Biosplice Therapeutics
- Class Amides; Anti-inflammatories; Antirheumatics; Fluorinated hydrocarbons; Imidazoles; Indazoles; Pyridines; Small molecules
- Mechanism of Action Clk dual-specificity kinase inhibitors; DYRK kinase inhibitors; Wnt signalling pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Osteoarthritis
- Preclinical Intervertebral disc degeneration
Most Recent Events
- 18 Apr 2024 Biosplice Therapeutics plans to meet US FDA and other regulatory agencies for approval of lorecivivint
- 20 Feb 2024 Biosplice Therapeutics completes the phase-III STRIDES trial in Osteoarthritis in USA (Intra-articular) (NCT05603754)
- 13 Nov 2023 Updated efficacy and adverse events data from a phase III trial in Osteoarthritis released by Biosplice Therapeutics